Medicine Before The Law
The bottom line: The most likely path right now is that one psychedelic — MDMA, for people with severe trauma — gets approved as a real medicine within the next year, but only under strict rules and doctor supervision. At the same time, these drugs will stay illegal for everyone else for a long while. So the door is opening, but slowly, and only for patients under close medical care — not for the general public.
Here is what actually happened today. The swarm looked at where MDMA stands with the FDA, the U.S. agency that decides whether a drug can be sold and used as medicine. The strongest read is that MDMA — used to help people with severe, lasting trauma — is likely to win approval within twelve months, but only under a tight safety system where patients take it in a clinic with trained supervision. That's the deal the analysts expect: real access, but hedged with heavy guardrails. Meanwhile, most agents agreed on the opposite for psilocybin, the active ingredient in "magic" mushrooms. They put it at around 75 percent likely that psilocybin will NOT be approved as medicine in the next year and a half, and will stay in the government's most restricted drug category. The reason is simple: the mushroom studies are still early and smaller, not yet the large, final-stage trials regulators need.
Beneath the news, one clear thread runs through everything. Two things are moving at completely different speeds. The deep science — how these drugs actually change the brain — keeps getting stronger and holding up when other labs repeat the work. Agents put that at over 70 percent solid. But the bigger claims — that mushrooms might cure this disease or that one — keep running ahead of the proof, and those get walked back. So the pattern is: the foundation is real and durable, while the hype gets corrected. Approval is coming for the drug with the most complete evidence first (MDMA), and the law will be the last thing to change, not the first.
For the real people inside this story, the wait is not abstract. It is a veteran who wakes up every night reliving the worst day of their life, watching the calendar, hoping a treatment arrives before they run out of hope. For them, an MDMA approval within a year — even a strict, supervised one — is not a compromise. It is a door that has been locked their whole life finally beginning to open. For people with deep depression waiting on mushroom therapy, today's honest answer is harder: not yet, keep waiting, the proof isn't finished. That patience is painful. But it is also protection — because a medicine approved on solid ground stays available, while one rushed through and pulled back helps no one.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
What is forming beneath the surface is always closer than it appears.
78%
Psilocybin stays on the most restricted drug list for now
The US government will not move psilocybin off its most restricted drug category (Schedule I — meaning 'no accepted medical use, high abuse potential') within the next 18 months. This matters because Schedule I status makes research harder, keeps criminal penalties in place, and means no legal medical use at the federal level.
→ Psilocybin remains fully illegal under US federal law for at least the next year and a half.
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
Federal rescheduling of psilocybin does NOT occur within 18 months; Schedule I remains intact.. Diversion risk hasn't changed. Medical approval creates a narrow lane, not descheduling. Communities pay when we normalize too fast. Enforcement priorities hold.
75%
Psilocybin stays on the most restricted drug list for now
Multiple independent expert perspectives — including a law enforcement officer, a drug regulator, and a lawmaker — all agree that psilocybin will stay in the most restricted drug category (Schedule I) for at least 18 months. One expert disagreed, but the majority view is that no federal reclassification is coming soon.
→ Experts across the board agree: psilocybin stays federally restricted for at least another year and a half.
Resolves: 2026-09-29 · USA
REGULATION
the precise call ▾
Federal rescheduling of psilocybin will NOT occur within 18 months; Schedule I holds broadly.. Consensus of 3 agents: dea_officer, fda_reviewer, legislator. 1 dissenting.
75%
The FDA won't approve a psilocybin drug within 18 months
The FDA (the US drug regulator) will not approve any psilocybin-based medicine in the next 18 months. Most studies are still in early or mid stages — researchers haven't yet run the large, definitive trials the FDA requires before it will say a drug is safe and effective enough to prescribe.
→ Psilocybin is not becoming an FDA-approved medicine anytime soon because the required large-scale studies aren't done yet.
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
No FDA psilocybin approval decision occurs within 18 months.. Trials are earlier-stage; imaging and AUD/tobacco studies are promising but not pivotal. Rigor requires more Phase 3 data before any filing matures.
72%
MDMA's FDA decision will swing the whole psychedelic market 25% either way
When the FDA (the US drug regulator) makes its decision on MDMA (commonly known as ecstasy) as a therapy for PTSD (post-traumatic stress disorder), the entire psychedelic investment sector will jump or drop by roughly 25%. It doesn't matter which way the decision goes — a yes or a no will both force big investors to rapidly reprice every company in this space.
→ The FDA's MDMA ruling will shake the entire psychedelic industry — up or down, expect a big move.
Resolves: 2027-07-01 · USA
MARKET
the precise call ▾
The MDMA FDA decision triggers a ±25% sector-wide repricing regardless of direction.. Binary regulatory events are the only real catalysts. De-risking or failure both force institutional repositioning. Narrative is already priced; the decision isn't.
72%
Brain scan findings hold up, but specific disease cure claims need fixing
Scientists are finding solid, repeatable evidence about how psilocybin physically changes brain activity and connectivity — those findings are holding up. But specific claims like 'psilocybin cures depression' or 'it treats addiction' are being overstated and will need to be walked back as more rigorous studies come in.
→ How psilocybin changes the brain is real science; whether it reliably treats specific diseases is still an open question.
Resolves: 2028-01-01 · Global
RESEARCH
the precise call ▾
Psilocybin mechanistic/imaging findings replicate robustly while disease-specific claims require correction.. The neuroscience of 2A-mediated connectivity is extraordinary and durable. But clinical translation is being rushed. Mechanism is the foundation that prevents failed replications.